MedTrace Logo

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

NCT06167642 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2025-06-06

No results posted yet for this study

Summary

This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.

Conditions

Interventions

DRUG

Ofatumumab

Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study

Sponsors & Collaborators

Principal Investigators

  • Shiv Saidha, MBBCh · Johns Hopkins University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06167642 on ClinicalTrials.gov